首页> 外文期刊>Translational psychiatry. >The DNA methylome in panic disorder: a case-control and longitudinal psychotherapy-epigenetic study
【24h】

The DNA methylome in panic disorder: a case-control and longitudinal psychotherapy-epigenetic study

机译:恐慌症中的DNA甲基族:一种案例控制和纵向心理治疗 - 表观遗传研究

获取原文
           

摘要

In panic disorder (PD), epigenetic mechanisms such as DNA methylation of candidate genes have been suggested to play a key role at the intersection of genetic and environmental factors. On an epigenome-wide level, however, only two studies in PD patients have been published so far, while to date no study has intra-individually analyzed dynamic epigenetic correlates of treatment-response in PD on a DNA methylome level. Here, an epigenome-wide association study (EWAS) was performed in a sample of 57 PD patients and matched healthy controls using the Illumina MethylationEPIC BeadChip, along with a longitudinal approach assessing changes on the DNA methylome level corresponding to clinical effects of a manualized six-week cognitive-behavioral therapy (CBT) in PD. While no epigenome-wide significant hits could be discerned, top suggestive evidence was observed for decreased methylation in PD at cg19917903 in the Cilia and Flagella Associated Protein 46 (CFAP46) gene, and for an increase in methylation after CBT at cg06943668 in the Interleukin 1 Receptor Type 1 (IL1R1) gene in treatment responders to CBT. Additional exploratory analyses based on biological validity and a combined statistical/biological ranking point to further new potential PD risk genes such as the CCL4L1 or GMNN genes, and suggest dynamic methylation of, e.g., the ZFP622 and the SLC43A2 genes along with response to CBT. These EWAS and first longitudinal epigenome-wide pilot data in PD add to the emerging candidate gene-based body of evidence for epigenetic mechanisms to be involved in PD pathogenesis and to possibly constitute dynamic biological correlates of therapeutic interventions.
机译:在恐慌障碍(PD)中,已经提出了表观遗传机制,例如DNA甲基化的候选基因的甲基化,在遗传和环境因素的交叉处发挥关键作用。然而,在外观血键的水平上,迄今为止只发布了PD患者的两项研究,迄今为止,迄今为止没有研究在DNA甲基叶片水平上单独分析了PD治疗反应的动态表观遗传相关性。在这里,在57个PD患者的样品中进行外延一组关联研究(EWAs),并使用Illumina甲基化珠芯片匹配的健康对照,以及评估对应于手动六种临床效应的DNA甲基叶绿体水平的变化的纵向方法-WEEK在PD中的认知行为疗法(CBT)。虽然可以辨别出外膜内聚烯簇宽的显着命中,但在纤毛和鞭毛相关蛋白质46(CFAP46)基因中的CG19917903中的PD中甲基化降低,并且在白细胞介素1的CG06943668中增加甲基化的甲基化的甲基化的甲基化的最佳提示证据受体1(IL1R1)基因治疗响应者对CBT。基于生物有效性和组合统计/生物排名点的额外探索性分析,进一步的新潜在的PD风险基因,如CCL4L1或GMNN基因,并提出例如ZFP622和SLC43A2基因的动态甲基化以及对CBT的响应。这些ewas和PD中的第一纵向外观纤维组型导频数据增加了新兴候选基因的基于表观遗传机制的基于PD发病机制,并可能构成治疗干预的动态生物学相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号